This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Insiders And Analysts Agree These 5 Stocks Are Trading Below Value

Stocks in this article: FOLD KEYN KTOS STAA STEI

2. STAAR Surgical Company ( STAA): Designs, develops, manufactures, and sells implantable lenses for the cataracts and refractive surgery. Market cap at $202.4M, most recent closing price at $5.53. Of the 5 analysts that have set a target price on the stock, the lowest price target stands at $7. This implies a potential upside of 26.58% from current levels around $5.53. Over the last six months, insiders were net buyers of 271,585 shares, which represents about 1.05% of the company’s 25.80M share float.

 

3. Stewart Enterprises Inc. ( STEI): Provides funeral and cemetery products and services in the death care industry in the United States and Puerto Rico. Market cap at $628.4M, most recent closing price at $7.36. Of the 5 analysts that have set a target price on the stock, the lowest price target stands at $9. This implies a potential upside of 20.80% from current levels around $7.45. Over the last six months, insiders were net buyers of 1,314,895 shares, which represents about 2.1% of the company’s 62.63M share float.

 

4. Kratos Defense & Security Solutions, Inc. ( KTOS): Provides engineering, war fighter, security, and information technology services, solutions, and products in the United States. Market cap at $249.61M, most recent closing price at $4.41. Of the 7 analysts that have set a target price on the stock, the lowest price target stands at $5. This implies a potential upside of 15.74% from current levels around $4.32. Over the last six months, insiders were net buyers of 11,127,500 shares, which represents about 25.1% of the company’s 44.34M share float.

 

5. Amicus Therapeutics, Inc. ( FOLD): Focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs for the treatment of various human genetic diseases. Market cap at $271.86M, most recent closing price at $5.51. Of the 5 analysts that have set a target price on the stock, the lowest price target stands at $6. This implies a potential upside of 15.38% from current levels around $5.2. Over the last six months, insiders were net buyers of 2,949,580 shares, which represents about 11.93% of the company’s 24.73M share float.

 

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs